KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Operating Leases (2020 - 2025)

Novavax (NVAX) has 4 years of Operating Leases data on record, last reported at $76.7 million in Q4 2024.

  • For Q4 2024, Operating Leases fell 9.25% year-over-year to $76.7 million; the TTM value through Dec 2024 reached $76.7 million, down 9.25%, while the annual FY2024 figure was $76.7 million, 9.25% down from the prior year.
  • Operating Leases reached $76.7 million in Q4 2024 per NVAX's latest filing, down from $84.5 million in the prior quarter.
  • Across five years, Operating Leases topped out at $84.5 million in Q4 2023 and bottomed at $39.1 million in Q4 2021.
  • Average Operating Leases over 4 years is $70.4 million, with a median of $79.0 million recorded in 2022.
  • Peak YoY movement for Operating Leases: soared 107.9% in 2022, then dropped 9.25% in 2024.
  • A 4-year view of Operating Leases shows it stood at $39.1 million in 2021, then skyrocketed by 107.9% to $81.3 million in 2022, then rose by 3.91% to $84.5 million in 2023, then fell by 9.25% to $76.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $76.7 million in Q4 2024, $84.5 million in Q4 2023, and $81.3 million in Q4 2022.